Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 33,158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Chiropractic Adjustments on Brain Function Using Quantitative Encephalography

NCT01953614
View directory record Official record
Conditions
Brain Function
Interventions
Chiropractic adjustment, Sham adjustment
Other
Lead sponsor
Life University
Other
Eligibility
10 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 3 Interventional

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

NCT06584916
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 7, 2026, 9:14 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of a Multi-strain Probiotic on Acclimatization to High Altitude

NCT06552806
View directory record Official record
Conditions
Probiotics
Interventions
SLAB51
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bishop, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

Genetic Effects on Dopamine Response to an Opiate

NCT01878006
View directory record Official record
Conditions
Polymorphism-Genetic, Pain, Addiction
Interventions
Morphine, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Nov 7, 2026, 9:14 AM EST
Terminated Phase 4 Interventional Results available

Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor

NCT01519765
View directory record Official record
Conditions
Pregnancy
Interventions
Buccal Misoprostol, Vaginal misoprostol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 3 Interventional Results available

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

NCT04788511
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
50
States / cities
Fairhope, Alabama • Beverly Hills, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

NCT01152671
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Glendale, California • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 4 Interventional

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044
View directory record Official record
Conditions
Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions
Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Nov 7, 2026, 9:14 AM EST
Recruiting Phase 2 Interventional

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044
View directory record Official record
Conditions
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions
LY4268989, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
52
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 9:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition for Brain and Body Health (BB-Health) Feasibility Trial

NCT05542199
View directory record Official record
Conditions
Cognition, Obesity
Interventions
Multicomponent nutrition supplement (MCNS), Behavioral weight loss program
Other · Behavioral
Lead sponsor
Tufts University
Other
Eligibility
55 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 7, 2026, 9:14 AM EST
Completed Not applicable Interventional Results available

Effect of Oxytocin on Craving and Therapy Response

NCT01827332
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Oxytocin, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Nov 7, 2026, 9:14 AM EST
Terminated Phase 2 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder

NCT00997087
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Flumazenil
Drug
Lead sponsor
Parkway Medical Center
Other
Eligibility
19 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 1 Interventional Results available

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01396187
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05231023, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Chula Vista, California • Miami, Florida • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Nov 7, 2026, 9:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wayfinding Intervention in High-Fidelity Long-Term Memory

NCT04253587
View directory record Official record
Conditions
Long-Term Memory Decline, Mild Cognitive Impairment
Interventions
LabyrinthVR, Placebo Games, Coherence, Tablet
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
62 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

A Study of Cytisinicline for Vaping Cessation in Adult Smokers

NCT05431387
View directory record Official record
Conditions
Vaping, E-Cig Use
Interventions
cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Lexington, Kentucky • Boston, Massachusetts • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01355016
View directory record Official record
Conditions
Drug Safety, Respiratory Syncytial Virus Infections
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 3 Interventional Results available

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

NCT00105521
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Sarizotan, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
30 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Nov 7, 2026, 9:14 AM EST
Recruiting Phase 2 Interventional

Study of PTC844 in Participants With Active Rheumatoid Arthritis

NCT07779616
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PTC844, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Chandler, Arizona • Flagstaff, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 7, 2026, 9:14 AM EST
Active, not recruiting Phase 2 Interventional

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

NCT05637216
View directory record Official record
Conditions
Radiation Induced Fibrosis
Interventions
Losartan 25 milligram capsule, Placebo
Drug
Lead sponsor
Shaw Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 3 Interventional

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01776606
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Nov 7, 2026, 9:14 AM EST
Active, not recruiting Not applicable Interventional

Efficacy of the Apollo System for Children With ADHD

NCT05308706
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
8 weeks of home based use.
Device
Lead sponsor
Michigan State University
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 7, 2026, 9:14 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Aerosol in a Dental Clinic

NCT04659928
View directory record Official record
Conditions
Covid19
Interventions
High volume evacuation (HVE), Extraoral vacuum aspirator (EVA), Hydrogen Peroxide, Placebo
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Nov 7, 2026, 9:14 AM EST
Terminated Not applicable Interventional Results available

Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

NCT00183430
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Sleep Initiation and Maintenance Disorders
Interventions
Prazosin, Placebo, Psychotherapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Nov 7, 2026, 9:14 AM EST
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 7, 2026, 9:14 AM EST